Karen A. Dawes

CIK: 0001261506

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

BRNS

Barinthus Biotherapeutics plc.

Director

RGEN

REPLIGEN CORP

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

BRNS
Barinthus Biotherapeutics plc.
Sep 9, 2026
Disposition(D)
Direct
1.7K shares-
RGEN
REPLIGEN CORP
May 14, 2026
Award(A)
Direct
995 shares-
RGEN
REPLIGEN CORP
Dec 17, 2025
Sale(S)
Direct
275 shares at avg. $161.00$44K
BRNS
Barinthus Biotherapeutics plc.
Jun 10, 2025
Award(A)
Share Option (Right to Buy)
Direct
20.2K shares-
RGEN
REPLIGEN CORP
May 15, 2025
Award(A)
Direct
973 shares-

		Type	Shares	Price		Ownership
Sep 9, 2026	BRNS Barinthus Biotherapeutics plc.	Disposition(D)	1,700	-	$0	Direct
May 14, 2026	RGEN REPLIGEN CORP	Award(A)	995	-	$0	Direct
Dec 17, 2025	RGEN REPLIGEN CORP	Sale(S)	275	$161.00	$44,275	Direct
Jun 10, 2025	BRNS Barinthus Biotherapeutics plc.	Award(A) Share Option (Right to Buy)	20,174	-	-	Direct
May 15, 2025	RGEN REPLIGEN CORP	Award(A)	973	-	-	Direct

1-5 of 5 transactions

About DAWES KAREN A

DAWES KAREN A (SEC CIK 0001261506) files insider reports with the SEC as Director of Barinthus Biotherapeutics plc. (BRNS) and Director of REPLIGEN CORP (RGEN).

Signal8 holds 5 ownership filings by DAWES KAREN A, all Form 4s, filed between May 19, 2025 and Sep 9, 2026. Those filings report 5 transactions, from May 15, 2025 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DAWES KAREN A's filings is in GERMANTOWN, MD.

Recent filings by DAWES KAREN A

Sep 9, 2026: Disposition to issuer transaction of BRNS shares (Form 4, code D).
May 14, 2026: Grant or award of RGEN shares (Form 4, code A).
Dec 17, 2025: Open-market sale of RGEN shares (Form 4, code S).
Jun 10, 2025: Grant or award of BRNS derivative securities (Form 4, code A).
May 15, 2025: Grant or award of RGEN shares (Form 4, code A).

Other insiders filing for Barinthus Biotherapeutics plc. (BRNS)

Oxford Science Enterprises plc, Officer
Wright Robin, Director
Scheeren Joseph, Director
Phillips Anne M., Director
Morgon Pierre A., Director
Hooftman Leon, Chief Medical Officer

How to read Form 4 transaction codes